Heart transplantation and COVID-19 in the early postoperative period in hypertrophic cardiomyopathy: a clinical case-Reference-Cited by-同舟云学术

Heart transplantation and COVID-19 in the early postoperative period in hypertrophic cardiomyopathy: a clinical case

Published:2022-05-17 Issue:2 Volume:24 Page:58-64
ISSN:2412-6160
Container-title:Russian Journal of Transplantology and Artificial Organs
language:
Short-container-title:RJTAO

Author:

Zaynetdinov M. R.¹,Mukharyamov M. N.²,Dzhordzhikiya R. K.²,Vagizov I. I.³,Miroshnichenko M. A.³,Abdulyanov I. V.³,Khamzin R. R.³,Abdulganieva D. I.⁴,Dyakova E. V.⁵,Bayalieva A. Zh.¹,Gizatullina N. F.²,Stekolshchikova N. Yu.³,Minnullin M. M.⁵,Khairullin R. N.³

Affiliation:

1. Kazan State Medical University

2. Kazan State Medical University; Interregional Clinical Diagnostic Center

3. Interregional Clinical Diagnostic Center

4. Kazan State Medical University; Republican Clinical Hospital

5. Republican Clinical Hospital

Abstract

Hypertrophic cardiomyopathy (HCM) is a disease that is usually unresponsive to conservative pathogenetic therapy. It does not have clearly developed surgical correction algorithms. Heart transplantation (HTx) is the sole therapeutic option when drug therapy is ineffective and surgical reduction of hypertrophic myocardium is not feasible. There are only sporadic reports in the literature about HTx for HCM. The novel coronavirus disease 2019 (COVID-19) pandemic has significantly affected the work of cardiac surgical units and, in particular, organ transplantation activities. This paper presents a clinical case of an HCM patient who underwent HTx, complicated by COVID-19 infection in the early postoperative period.

Publisher

V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs

Subject

Transplantation,Immunology and Allergy

Reference14 articles.

1. Gabrusenko SA, Gudkova AYa, Koziolova NA, Alexandrova SA, Berseneva MI, Gordeev ML et al. 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2021; 26 (5): 269–333. [In Russ.]. doi: 10.15829/1560-4071-2021-4541.

2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142: 533–557. doi: 10.1161/CIR.0000000000000938.

3. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC Guidelines on diagnosis and managementof hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Managementof Hypertrophic Cardiomyopathy ofthe European Society of Cardiology (ESC). Eur Heart J. 2014; 35 (39): 2733–2779. doi: 10.1093/eurheartj/ehu284.

4. Krylova NS, Kovalevskaya EA, Poteshkina NG, Demkina AE, Khashieva FM. Sudden death in hypertrophic cardiomyopathy: search for new risk factors. Russian Journal of Cardiology. 2017; 2(142): 62–67. [In Russ.]. doi: 10.15829/1562-4071-2017-2-62-67.

5. Chumakova OS. Hypertrophic cardiomyopathy in elderty: causes, diagnostic and treatment approaches. Therapeutic Archive. 2020; 92 (9): 63–69. [In Russ.]. doi: 10.26442/00403660.2020.09.000558.